A long‐acting pegylated recombinant human growth hormone (Jintrolong®) in healthy adult subjects: Two single‐dose trials evaluating safety, tolerability and pharmacokinetics.

Summary: What is known and objective: Jintrolong® is a pegylated recombinant human growth hormone (rhGH) (PEG‐rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single‐dose Jintrolo...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacy & Therapeutics Vol. 43; no. 5; pp. 640 - 647
Main Authors:	Guan, Y., He, F., Wu, J., Zhao, L., Wang, X., Huang, L., Zeng, G., Ren, B., Chen, J., Liao, X., Ma, Z., Chen, X., Zhong, G., Huang, M., Zhao, X.
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Wiley-Blackwell Oct2018
Online Access:	View this record in EBSCOhost